Overview of R2 Regimen for Relapsed Follicular Lymphoma

Video

Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R<sup>2</sup> regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br /> &nbsp;

Andre Goy, MD, chief, division of lymphoma, chairman and director, John Theurer Cancer Center, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide (Revlimid) plus rituximab (Rituxan), also known as the R2regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.

In this patient population, rituximab monotherapy was standard treatment, but this was not an appealing option for older patients. The data support R2

Recent Videos
Related Content
Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Jordyn Sava
November 22nd 2024
Article

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Nichole Tucker
July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer

Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer

Jordyn Sava
November 21st 2024
Article

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

Nichole Tucker
June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More